A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study

A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study

Azathioprine (AZA) has demonstrated efficacy in multiple randomized control trials (RCTs) for Relapsing-Remitting Multiple Sclerosis (RRMS). However, we still need comparative real-world data with other first-line disease-modifying therapies (DMTs). We aimed to assess AZA’s effectiveness regarding r...

Full description

Bibliographic Details
Main Authors: Arpit Agrawal, M. V. Padma Srivastava, Rohit Bhatia, Vinay Goyal, Mamta Bhushan Singh, Venugopalan Y. Vishnu, Anuj Prabhakar
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Brain Sciences
Subjects:
azathioprine
relapsing-remitting multiple sclerosis
first-line disease-modifying therapy
dimethyl fumarate
interferon beta-1a
teriflunomide
Online Access:https://www.mdpi.com/2076-3425/13/9/1249

Internet

https://www.mdpi.com/2076-3425/13/9/1249

Similar Items